• Welcome Guest
  • View Cart
  • Phone (US): 703.778.3080
  • 0Shopping Cart
  • Market Reports
  • Market Research Subscriptions
    • Knowledge Center
  • Custom Market Research
    • Quantitative Market Research
    • Qualitative Market Research
    • RateMyProduct
  • Blog
  • Featured
    • Free Downloads
    • View Webinars On-Demand
    • The IVD Market in 2023: $130 Billion and Growing
    • The Point of Care Testing Market
    • Immunoassays
  • About Us
    • Contact
  • Search
  • Menu Menu
  • Biotechnology
    • Next Generation Sequencing
    • Proteomics
    • Biopharmaceuticals
    • Instrumentation & Equipment
    • Emerging Technologies
  • Pharmaceuticals
    • Vaccines
    • Drug Delivery
    • Over-the-Counter
    • Drug Discovery
    • Cancer Treatment
    • Manufacturing & Packaging
    • Prescription Drugs
  • Diagnostics
    • Molecular Assays
    • Point-of-Care
    • Immunoassays
    • Infectious Disease
    • Clinical Chemistry
    • Oncology & Hematology
    • Lab Testing Services
    • Medical Imaging
  • Healthcare
    • Information Technology
    • Facilities & Settings
    • Insurance & Managed Care
  • Medical Devices
    • Wound Care
    • Drug Delivery
    • Equipment
    • Surgical
  • Login
Awaiting product image

Filter your search

Search Report Keyword
Price
CATEGORIES
  • Biotechnology Market Research
  • cell and gene therapy
  • cell therapy
  • Diagnostics Market Research
  • gene therapy
  • Healthcare Information Technology
  • Healthcare Market Research
  • in vitro diagnostic
  • IVD
  • life sciences
  • Medical Devices Market Research
  • Molecular & Nucleic Acid Testing
  • Pharmaceuticals Market Research
  • Point-of-Care Diagnostics
  • sciences
  • vaccines

Knowledge Center Sidebar

Most Popular Research

  • Cell and Gene Therapy Business Outlook
  • The Worldwide Market for In Vitro Diagnostic Tests, 14th Edition
  • Clinical Diagnostics MasterFile
  • The Global Market for Medical Devices, 11th Edition
  • The World Market for Molecular Diagnostics Tests, 10th Edition
  • Remote Patient Monitoring and Telehealth Markets, 12th Edition

Cell Therapy and Gene Therapy Markets, 2021-2031

$6,000.00 – $12,000.00

Clear
SKU: 22-021 Categories: cell and gene therapy, cell therapy, gene therapy, Pharmaceuticals, Pharmaceuticals Market Research, sciences Tags: Cardiovascular and Blood Disorders, cell and gene therapy, cell therapy, Dermatology, gene therapy, Musculoskeletal Cell Therapy Market, Oncology, Ophthalmic Conditions Pages: 272
  • Description
  • Table of Contents
  • Latest reports

Description

Authoritative Information on Cell and Gene Therapy Markets

Cell Therapy And Gene Therapy Markets, 2021-2031 from Kalorama Information presents the market in segments that provide an overview of disease epidemiology, market estimates and forecasts, and competitive summary of leading providers:

  • Cell and Gene Therapy Market Summary by Product Segment, 2021-2031 ($ millions) (Dermatological, Cardiovascular – Blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions, Total Market)
  • Cell and Gene Therapy Market Summary by Method, 2021-2031 ($ millions) (Cell Therapy, Gene Therapy, Total Market)
    Cell and Gene Therapy Market Summary by Geographical Region, 2021-2031 ($ millions) (United States, Europe/European Union, Other Countries, Global Market)
  • Cell and Gene Therapy Market Summary for United States by Product Segment, 2021-2031 ($ millions) (Dermatological, Cardiovascular – Blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions, Total)
  • S. Cell and Gene Therapy Market, Distribution by Product Segment (Dermatological, Cardiovascular-blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions), 2020 (%)
  • Europe Cell and Gene Therapy Market, Distribution by Product Segment (Dermatological, Cardiovascular-blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions), 2020 (%)
  • Other Countries Cell and Gene Therapy Market, Distribution by Product Segment (Dermatological, Cardiovascular-blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions), 2020 (%)
  • Estimated Cell and Gene Therapy Sales by Leading Competitor, 2021 Sales ($ millions)

Scope

The report examines developments in cell and gene therapy markets by condition/disorder, including principal products, trends in research and development, market breakdown of cell and gene therapies, regional market summary, and competitor summary.

The following conditions/disorders are covered:

  • Dermatology, including:
    • Dermatology Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2026 and 2031 ($ millions) (Stem cells, Skin cells)
    • Dermatology Cell and Gene Therapy Market by General Indication, Estimated 2021, Projected 2026 and 2031 ($ millions) (Wound healing/treatment, Other indications [wrinkles, scar treatment])
    • Dermatology Cell and Gene Therapy Market by Country/Region, Estimated 2021, Projected 2026 and 2031 ($ millions) (United States, Europe/European Union, S. Korea, Other countries)
    • Dermatology Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2021 ($ millions)
  • Cardiovascular and Blood Disorders, including:
    • Cardiovascular and Blood Disorders Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2026 and 2031 ($ millions) (Stem cells, Gene therapy, Other cell therapies; Stromal cells)
    • Cardiovascular and Blood Disorders Cell and Gene Therapy Market by General Indication, Estimated 2021, Projected 2026 and 2031 ($ millions) (Cardiac disorders, Vascular disorders, Blood disorders, Hypercholesterolemia)
    • Cardiovascular and Blood Disorders Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2021 and Projected 2026, 2030 ($ millions) (United States, Europe, S. Korea, Japan, ROW)
  • Oncology, including:
    • Oncology Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2026 and 2031 ($ millions) (CAR-T, Cell immunotherapy, Gene therapy, Other cell therapy)
    • Oncology Cell and Gene Therapy Market by General Indication, Estimated 2021, Projected 2026 and 2031 ($ millions) (Blood cancers, Prostate cancer, Melanoma, Other cancers)
    • Oncology Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2021 and Projected 2026, 2030 ($ millions) (United States, Europe, ROW)
    • Oncology Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2021 ($ millions)
  • Ophthalmic Conditions, including:
    • Ophthalmology Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2026 and 2031 ($ millions) (Stem cells, Gene therapy, Other cell therapy)
    • Ophthalmology Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2021 and Projected 2026, 2030 ($ millions) (United States, Europe, Other countries)
  • Musculoskeletal Conditions and Disorders, including:
    • Musculoskeletal Cell Therapy Market, Estimated 2021 and Projected 2026 and 2031 ($ millions)
    • Musculoskeletal Cell and Gene Therapy Market by General Indication, Estimated 2021, Projected 2026 and 2031 ($ millions) (Cartilage Defect/Damage Repair, Bone Defect/Damage Repair, Others [tendon damage, osteoarthritis])
    • Musculoskeletal Cell and Gene Therapy Market by Country/Region, Estimated 2021, Projected 2026 and 2031 ($ millions) (United States, Europe/European Union, S. Korea, Other countries)
    • Musculoskeletal Cell Therapy Competitor Market Share, Reported and Estimated 2021 ($ millions)
  • Other Conditions, including:
    • Other Conditions Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2026 and 2031 ($ millions) (Cell therapy, Gene therapy, Gene-modified cell therapy)
    • Other Conditions Cell and Gene Therapy Market by Country/Region, Estimated 2021, Projected 2026 and 2031 ($ millions) (United States, Europe/European Union, S. Korea, Other countries)

Table of Contents

Chapter 1: Executive Summary

Overview

Scope and Methodology

Market Overview and Potential

  • Figure 1-1: Global Cell and Gene Therapy Market CAGR by Product Segment, 2021-2031

 

Chapter 2: Introduction to Cell and Gene Therapy

Introduction

Cell Therapy

  • Table 2-1: Adult vs. Embryonic Stem Cells

Gene Therapy

  • Table 2-2: Somatic vs. Germ Line Gene Therapy

Viral Vector System and New Developments

  • Table 2-3: Selected Examples of Viruses in Gene Therapy
  • Figure 2-1: Viral Vector Use in Commercialized Cell and Gene Therapies

Non-viral Systems for Transporting Genes

Gene Editing

Cell and Gene Therapy: Characteristics

  • Table 2-4: Cell Therapy vs Gene Therapy

Staffing

Manufacturing Process for CAR-T

Leukapheresis

Activation

Transduction

Expansion

Cell and Gene Therapy Manufacturing Processes

  • Table 2-5: Manufacturing Process Time for Select Autologous Cell and Gene Therapies (current and discontinued therapies)
  • Figure 2-2: Manufacturing Process Time for Select Autologous Cell and Gene Therapies (current and discontinued therapies)
  • Table 2-6: Selected Recent Viral Vector Company Expansion

Cost

Reimbursement

Logistics

Mergers and Acquisitions

  • Table 2-7: Selected Company Mergers and Acquisitions in the Cell and Gene Therapy Market

Partnerships, Agreements and Collaborations

  • Table 2-8: Selected  Company Partnerships, Agreements and Collaborations in the Cell and Gene Therapy Market

Financing and Funding Deals

  • Table 2-9: Recent Cell and Gene Therapy Recent Financing Deals

Regulatory Developments

  • Figure 2-3: FDA Cell & Gene Therapy Percent of Projects with Orphan Drug and/or Fast Track Status

Fast Track

Orphan Drug

Breakthrough Therapy

Accelerated Approval

Priority Review

  • Table 2-10: Regulatory Actions and Guidelines for Cell and Gene Therapy by Select Country

Individualized Gene Therapy Approval Process

Development and Pipeline Overview

Development Progress

  • Figure 2-4: Global Cell and Gene Therapy Development Progress (phase I through phase III), as of January 2022
  • Figure 2-5: Global Cell and Gene Therapy Development Progress by Phase, as of January 2022

Development by Condition/Disorder

  • Figure 2-6: Global Development of Cell and Gene Therapies by Target

Global Participation in Cell and Gene Therapy Development

  • Figure 2-7: Global Development Activity of Cell and Gene Therapies by Country, as of January 2022

Phase III Development

  • Table 2-11: Phase III Development ¾ Cell and Gene Therapies, Select Projects
  • Figure 2-8: Cell and Gene Therapy: Top 30 Developers (Phase I through Submission)

End User

Hospitals

Research Institutes

Wound Care Centers

Cancer Centers

 

Chapter 3: Cell and Gene Therapy Markets in Dermatology

Overview

  • Table 3-1: Wound Prevalence by Type

Market Outlook

  • Figure 3-1: Cell and Gene Therapy Markets in Dermatology, 2021-2031 ($ millions)

Principal Products

Adipocel

Apligraf

CureSkin

Dermagraft

Epicel

Grafix

Holoderm

Kaloderm

KeraHeal/KeraHeal-Allo

LaViv

Orcel

Quencell

RECELL

Rosmir

Stempeutics/Cutisera

StrataGraft

Stravix

TransCyte

  • Table 3-2: Cell and Gene Therapy in Dermatological Diseases and Disorders
  • Figure 3-2: Dermatology Cell and Gene Therapy Approvals by Year or Year Range, through 2021

Trends in Research and Development

  • Table 3-3: Dermatology Cell and Gene Therapies in Development by Phase, January 2022 Data
  • Table 3-4: Dermatology Cell and Gene Therapies in Development by Method, January 2022 Data

Phase III Development

  • Table 3-5: Select Dermatology Phase III Cell and Gene Therapy Developments, through January 2022

Orphan Drug, Fast Track, Breakthrough Designations

  • Table 3-6: Orphan Drug, Fast Track and Breakthrough Designations for Dermatology Cell and Gene Therapies in Development (Phase I through III), through January 2022

Market Breakdown of Cell and Gene Therapies

  • Table 3-7: Dermatology Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2031 ($ millions)
  • Figure 3-3: Dermatology Cell and Gene Therapy Market Distribution by Product Type, 2021 (%)

Dermatology Cell and Gene Therapy Market by Indication

  • Table 3-8: Dermatology Cell and Gene Therapy Market by General Indication, Estimated 2021, Projected 2031 ($ millions)

Regional Market Summary

  • Figure 3-4: Dermatology Cell and Gene Therapy Approvals by Country/Region, through 2021
  • Table 3-9: Dermatology Cell and Gene Therapy Market by Country/Region, Estimated 2021, Projected 2031 ($ millions)
  • Figure: 3-5: Dermatology Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2021 and Projected 2031 ($ millions)

Competitor Summary

  • Table 3-10: Dermatology Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2021 ($ millions)

 

Chapter 4: Cell and Gene Therapy Markets in Cardiovascular and Blood Disorders

Overview

Cardiovascular Disease

Selected Blood Disorders

Market Outlook

  • Figure 4-1: Cell and Gene Therapy Markets in Cardiovascular and Blood Disorders, 2021-2031, ($ millions)

Principal Products

Collategene

Hearticellgram

HeartSheet

Leqvio

Neovasculgen

Stempeucel

Zynteglo

Cord Blood Products

  • Table 4-1:  Selected Cell and Gene Therapy in Cardiovascular and Blood Disorders
  • Figure 4-2: Cardiovascular and Blood Disorders Cell and Gene Therapy Approvals by Year, through 2021

Trends in Research and Development

  • Table 4-2: Cardiovascular and Blood Disorders Cell and Gene Therapies in Development by Phase, January 2022 Data
  • Table 4-3: Cardiovascular and Blood Disorders Cell and Gene Therapies in Development by Method, January 2022 Data

Phase III Development

  • Table 4-4: Select Cardiovascular and Blood Disorder Phase III Cell and Gene Therapy Developments, through January 2022

Orphan Drug, Fast Track, Breakthrough Designations

  • Table 4-5: Orphan Drug, Fast Track and Breakthrough Designations for Cardiovascular and Blood Disorder Cell and Gene Therapies in Development (Phase I through III), through January 2022

Market Breakdown of Cell and Gene Therapies

  • Table 4-6: Cardiovascular and Blood Disorders Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2031 ($ millions)
  • Figure 4-3: Cardiovascular and Blood Disorders Cell and Gene Therapy Market Distribution by Product Type, 2021 (%)

Cardiovascular and Blood Disorders Cell and Gene Therapy Market by Indication

  • Table 4-7: Cardiovascular and Blood Disorders Cell and Gene Therapy Market by General Indication, Estimated 2021 and Projected 2031($ millions)

Regional Market Summary

  • Figure 4-4: Cardiovascular and Blood Disorders Cell and Gene Therapy Approvals by Country/Region, through 2021
  • Table 4-8: Cardiovascular and Blood Disorders Cell and Gene Therapy Market by Country/Region, Estimated 2021 and Projected 2031($ millions)
  • Figure: 4-5: Cardiovascular and Blood Disorders Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2021 and Projected 2031($ millions)

Competitor Summary

 

Chapter 5: Cell and Gene Therapy Markets in Oncology

Overview

Biochemistry of Cancer Cells

Causes of Cancer Growth

Environmental Factors, DNA, RNA

  • Table 5-1: Virus Association with Human Cancer

Cellular Oncogenes

Tumor Suppressor Genes

Global Cancer Burden

  • Figure 5-1: Estimated Number of New Cases from 2020 to 2040, Both Sexes, Age 0-85+, All Cancers
  • Figure 5-2: Incidence of Cancer by Type, 2020
  • Figure 5-3: Distribution of Cancer Incidence by Type, 2020

Market Outlook

  • Figure 5-4: Cell and Gene Therapy Markets in Oncology, 2021-2031 ($ millions)

Principal Products

Abecma

APCeden

Breyanzi

CreaVax-RCC

Gendicine

Imlygic

Immuncell-LC

Kymriah

Provenge

Tecartus

Yescarta

  • Table 5-2: Cell and Gene Therapy in Oncology
  • Figure 5-5: Oncology Cell and Gene Therapy Approvals by Year, through 2021

Trends in Research and Development

  • Table 5-3: Oncology Cell and Gene Therapies in Development by Phase, January 2022 Data
  • Table 5-4: Oncology Cell and Gene Therapies in Development by Method, January 2022 Data
  • Figure 5-6: Oncology Cell and Gene Therapy Development by Cancer Type, January 2022 Data (Phase I through Phase III)

Phase III Development

  • Table 5-5: Select Oncology Phase III Cell and Gene Therapy Developments, through January 2022

Orphan Drug, Fast Track, Breakthrough Designations

  • Table 5-6: Orphan Drug, Fast Track and Breakthrough Designations for Oncology Cell and Gene Therapies in Development (Phase I through III), FDA Reported, through March 2020

Market Breakdown of Cell and Gene Therapies

  • Table 5-7: Oncology Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2031 ($ millions)
  • Figure 5-7: Oncology Cell and Gene Therapy Market Distribution by Product Type, 2021 (%)

Oncology Cell and Gene Therapy Market by Cancer Type

  • Table 5-8: Oncology Cell and Gene Therapy Market by Cancer Type, Estimated 2021 and Projected 2031 ($ millions)
  • Figure 5-8: Oncology Cell and Gene Therapy Market by General Indication (leukemia, lymphoma, undefined blood cancer, prostate cancer, melanoma, multiple myeloma, other cancers), Estimated 2021 (%)

Regional Market Summary

  • Figure 5-9: Oncology Cell and Gene Therapy Approvals by Country/Region, through 2021
  • Table 5-9: Oncology Cell and Gene Therapy Market by Country/Region, Estimated 2021 and Projected 2031 ($ millions)
  • Figure: 5-10: Oncology Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2021 and Projected 2031 ($ millions)

Competitor Summary

  • Table 5-10: Oncology Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2021 ($ millions)

 

Chapter 6: Cell and Gene Therapy Markets in Ophthalmic Conditions

Overview

Market Outlook

  • Figure 6-1: Cell and Gene Therapy Markets in Ophthalmic Conditions, 2021-2031 ($ millions)

Principal Products

Holoclar

Luxturna

  • Table 6-1: Cell and Gene Therapy in Ophthalmic Conditions

Trends in Research and Development

  • Table 6-2: Ophthalmology Cell and Gene Therapies in Development by Phase, January 2022 Data
  • Table 6-3: Ophthalmology Cell and Gene Therapies in Development by Method, January 2022 Data

Phase III Development

  • Table 6-4: Select Ophthalmology Phase III Cell and Gene Therapy Developments, through January 2022

Orphan Drug, Fast Track, Breakthrough Designations

  • Table 6-5: Orphan Drug, Fast Track and Breakthrough Designations for Ophthalmology Cell and Gene Therapies in Development (Phase I through III), FDA Reported, through January 2022

Market Breakdown of Cell and Gene Therapies

  • Table 6-6: Ophthalmology Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2031 ($ millions)
  • Figure 6-2: Ophthalmology Cell and Gene Therapy Market Distribution by Product Type, 2021 (%)

Regional Market Summary

  • Table 6-7: Ophthalmology Cell and Gene Therapy Market by Country/Region, Estimated 2021 and Projected 2031 ($ millions)
  • Figure: 6-3: Ophthalmology Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2021 and Projected 2031 ($ millions)

Competitor Summary

 

Chapter 7: Cell and Gene Therapy Markets in Musculoskeletal Conditions and Disorders

Overview

Market Outlook

  • Figure 7-1: Cell and Gene Therapy Markets in Musculoskeletal Conditions and Disorders, 2021-2031 ($ millions)

Principal Products

AlloStem

BIO4

Carticel

Cartiform

CartiLife

Cartistem

Chondron

JACC

MACI

Ortho-ACI and Ortho-ATI

Ossron

Osteocel and Osteoplus

Spherox

Trinity Elite and Trinity Evolution

  • Table 7-1: Cell and Gene Therapy in Musculoskeletal Diseases and Disorders
  • Figure 7-2: Musculoskeletal Cell and Gene Therapy Approvals by Year or Year Range, through 2021

Trends in Research and Development

  • Table 7-2: Musculoskeletal Cell and Gene Therapies in Development by Phase, January 2022 Data
  • Table 7-3: Musculoskeletal Cell and Gene Therapies in Development by Method, January 2022 Data

Phase III Development

  • Table 7-4: Select Musculoskeletal Phase III Cell and Gene Therapy Developments, through January 2022

Market Breakdown of Cell and Gene Therapies

  • Table 7-5: Musculoskeletal Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2031 ($ millions)

Musculoskeletal Cell and Gene Therapy Market by Indication

  • Table 7-6: Musculoskeletal Cell and Gene Therapy Market by General Indication, Estimated 2021 and Projected 2031($ millions)
  • Figure 7-3: Musculoskeletal Cell and Gene Therapy Market by General Indication (cartilage treatment, bone treatment and other indications), Estimated 2021 (%)

Regional Market Summary

  • Figure 7-4: Musculoskeletal Cell and Gene Therapy Approvals by Country/Region, through 2021
  • Table 7-7: Musculoskeletal Cell and Gene Therapy Market by Country/Region, Estimated 2021 and Projected 2031 ($ millions)
  • Figure: 7-5: Musculoskeletal Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2021 and Projected 2031($ millions)

Competitor Summary

  • Table 7-8: Musculoskeletal Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2021 ($ millions)

 

Chapter 8: Cell and Gene Therapy Markets in Neurological-Related Disorders

Overview

Market Outlook

  • Figure 8-1: Cell and Gene Therapy Markets in Neurological-Related Conditions, 2021-2031, ($ millions)

Principal Products

Libmeldy

NeuroNata-R

Onpattro

SKYSONA

Stemirac

Zolgensma

  • Table 8-1: Cell and Gene Therapy in Neurological Diseases and Disorders

Trends in Research and Development

Phase III Development

  • Table 8-2: Select Neurological Phase III Cell and Gene Therapy Developments, through January 2022

Orphan Drug, Fast Track, Breakthrough Designations

  • Table 8-3: Orphan Drug, Fast Track and Breakthrough Designations for Neurological Cell and Gene Therapies in Development (Phase I through III), FDA Reported, through January 2022

Market Breakdown of Cell and Gene Therapies

  • Table 8-4: Neurological Conditions Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2031($ millions)
  • Figure 8-2: Neurological Conditions Cell and Gene Therapy Market Distribution by Product Type, 2021 (%)

Regional Market Summary

  • Table 8-5: Neurological Conditions Cell and Gene Therapy Market by Country/Region, Estimated 2021 and Projected 2031($ millions)
  • Figure 8-3: Neurological Conditions Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2021 and Projected 2031($ millions)

Competitor Summary

  • Table 8-6: Neurological Conditions Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2021 ($ millions)

 

Chapter 9: Cell and Gene Therapy Markets in Other Conditions

Overview

Market Outlook

  • Figure 9-1: Cell and Gene Therapy Markets in Other Conditions, 2021-2031, ($ millions)

Principal Products

Alofisel

Cupistem

Givlaari

Glybera

Oxlumo

Rethymic

Ryplazim

Strimvelis

Temcell/Prochymal/Ryoncil

  • Table 9-1: Cell and Gene Therapy in Other Diseases and Disorders

Trends in Research and Development

Market Breakdown of Cell and Gene Therapies

  • Table 9-2: Other Conditions Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2031($ millions)
  • Figure 9-2: Other Conditions Cell and Gene Therapy Market Distribution by Product Type, 2021 (%)

Regional Market Summary

  • Table 9-3: Other Conditions Cell and Gene Therapy Market by Country/Region, Estimated 2021 and Projected 2031($ millions)
  • Figure 9-3: Other Conditions Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2021 and Projected 2031($ millions)

Competitor Summary

 

Chapter 10: Cell and Gene Therapy Market Review

Market Influences

Global Demographics

  • Table 10-1: Global Population, through 2050 (population in millions)
  • Figure 10-1: Global Population Trends, Total Population vs. Age 65+ Population, 2000-2050

Cost Containment

  • Table 10-2: Cost Comparisons for Selected Commercialized Cell and Gene Therapies

Cell and Gene Therapy and Viral Vector Shortages

Global Market Summary

  • Table 10-3: Cell and Gene Therapy Market Summary by Product Segment, 2021-2031 ($ millions)
  • Figure 10-2: Cell and Gene Therapy Market Summary by Product Segment, 2021-2031
  • Figure 10-3: Cell and Gene Therapy Market, Distribution of Sales by Product Segment, 2021

Cell vs. Gene Therapy Markets

  • Table 10-4: Cell and Gene Therapy Market Summary by Method, 2021-2031 ($ millions)
  • Figure 10-4: Cell and Gene Therapy Market, Distribution of Sales by Method, 2021

Regional Market Overview

  • Table 10-5: Cell and Gene Therapy Market Summary by Geographical Region, 2021-2031 ($ millions)

United States

  • Table 10-6: Cell and Gene Therapy Market Summary for United States by Product Segment, 2021-2031 ($ millions)
  • Figure 10-5: U.S. Cell and Gene Therapy Market, Distribution by Product Segment (dermatology, cardiovascular-blood, oncology, ophthalmology, musculoskeletal, neurology, other conditions), 2021 (%)
  • Table 10-7: Major Cell and Gene Therapy Product Approvals, FDA

Europe/European Union

  • Table 10-8: Cell and Gene Therapy Market Summary for Europe/European Union by Product Segment, 2021-2031 ($ millions)
  • Figure 10-6: Europe Cell and Gene Therapy Market, Distribution by Product Segment (dermatology, cardiovascular-blood, oncology, ophthalmology, musculoskeletal, neurology, other conditions), 2021 (%)
  • Table 10-9: Major Cell and Gene Therapy Approvals by EMA

Other Countries

  • Table 10-10: Cell and Gene Therapy Market Summary for Other Countries by Product Segment, 2021-2031 ($ millions)
  • Figure 10-7: Other Countries Cell and Gene Therapy Market, Distribution by Product Segment (dermatology, cardiovascular-blood, oncology, ophthalmology, musculoskeletal, neurology, other conditions), 2021 (%)
  • Table 10-11: Select Major Cell and Gene Therapy Approvals by Various Regulatory Authorities

Competitor Ranking in Cell and Gene Therapy Markets

  • Table 10-12: Estimated Cell and Gene Therapy Sales by Leading Competitor, 2021 Sales ($ millions)
  • Figure 10-8: Cell and Gene Therapy Market Share Estimates, 2021

 

Chapter 11: Market Participants

Leading Influencers

Advaxis, Inc. (Biosight Therapeutics)

  • Table 11-1: Advaxis Corporate Summary

Company Summary

Products

AlloSource

  • Table 11-2: AlloSource Corporate Summary

Company Summary

Products

Alnylam Pharmaceuticals, Inc.

  • Table 11-3: Alnylam Pharmaceuticals Corporate Summary

Company Summary

Products

Amgen

  • Table 11-4: Amgen Corporate Summary

Company Summary

Products

AnGes Inc.

  • Table 11-5: AnGes Corporate Summary

Company Summary

Products

Anterogen Co Ltd.

  • Table 11-6: Anterogen Corporate Summary

Company Summary

Products

Atara Biotherapeutics

  • Table 11-7: Atara Biotherapeutics Corporate Summary

Company Summary

Products

Athersys, Inc

  • Table 11-8: Athersys Corporate Summary

Company Summary

Products

BioCardia

  • Table 11-9: BioCardia Summary

Company Summary

Products

Biogen, Inc.

  • Table 11-10: Biogen Corporate Summary

Company Summary

Products

BioMarin Pharmaceuticals

  • Table 11-11: BioMarin Pharmaceuticals Corporate Summary

Company Summary

Products

bluebird bio, Inc.

  • Table 11-12: bluebird bio Corporate Summary

Company Summary

Products

BrainStorm Cell Therapeutics

  • Table 11-13: BrainStorm Cell Therapeutics Corporate Summary

Company Summary

Products

Bristol-Myers Squibb

  • Table 11-14:  Bristol-Myers Squibb Corporate Summary

Company Summary

Products

Caladrius Biosciences

  • Table 11-15: Caladrius Biosciences Corporate Summary

Company Summary

Products

Candel Therapeutics

  • Table 11-16: Candel Therapeutics Corporate Summary

Company Summary

Products

Castle Creek Biosciences

  • Table 11-17:  Castle Creek Corporate Summary

Company Summary

Products

Celyad Oncology

  • Table 11-18: Celyad Oncology Corporate Summary

Company Summary

Products

Cook Myosite, Inc

  • Table 11-19: Cook Myosite Corporate Summary

Company Summary

Products

Cytori Therapeutics, Inc

  • Table 11-20: Cytori Therapeutics Corporate Summary

Company Summary

Products

Dendreon Pharmaceuticals LLC

  • Table 11-21: Dendreon Corporate Summary

Company Summary

Products

FerGene, Inc/Ferring Pharmaceuticals

  • Table 11-22:  FerGene Corporate Summary

Company Summary

Products

Gamida Cell Ltd.

  • Table 11-23: Gamida Cell Corporate Summary

Company Summary

Products

GenSight Biologics S.A.

  • Table 11-24: GenSight Biologics Corporate Summary

Company Summary

Products

Gilead Sciences, Inc.

  • Table 11-25: Gilead Sciences Corporate Summary

Company Summary

Products

Gradalis, Inc

  • Table 11-26: Gradalis Corporate Summary

Company Summary

Products

Helixmith

  • Table 11-27:  Helixmith Corporate Summary

Company Summary

Products

Inovio Pharmaceuticals, Inc.

  • Table 11-28: Inovio Pharmaceuticals Corporate Summary

Company Summary

Products

Kiadis Pharma B.V. (Sanofi)

  • Table 11-29:  Kiadis Pharma Corporate Summary

Company Summary

Products

Medeor Therapeutics

  • Table 11-30: Medeor Therapeutics Corporate Summary

Company Summary

Products

MEDIPOST Co, Ltd.

  • Table 11-31: MEDIPOST Corporate Summary

Company Summary

Products

MeiraGTx

  • Table 11-32: MeiraGTxCorporate Summary

Company Summary

Products

Merck & Co., Inc.

  • Table 11-33: Merck & Co. Corporate Summary

Company Summary

Products

Mesoblast Ltd.

  • Table 11-34: Mesoblast Corporate Summary

Company Summary

Products

Neurotech Pharmaceuticals. Inc.

  • Table 11-35: Neurotech Corporate Summary

Company Summary

Products

Northwest Biotherapeutics, Inc.

  • Table 11-36: Northwest Biotherapeutics Corporate Summary

Company Summary

Products

Novartis AG

  • Table 11-37: Novartis Corporate Summary

Company Summary

Products

NuVasive Biologics

  • Table 11-38: NuVasive Biologics Corporate Summary

Company Summary

Products

Orchard Therapeutics

  • Table 11-39: Orchard Therapeutics Corporate Summary

Company Summary

Products

Organogenesis

  • Table 11-40: Organogenesis Corporate Summary

Company Summary

Products

Orthofix

  • Table 11-41: Orthofix Corporate Summary

Company Summary

Products

Osiris Therapeutics, Inc.( part of Smith & Nephew)

  • Table 11-42: Osiris Corporate Summary

Company Summary

Products

Pharmicell

  • Table 11-43: Pharmicell Corporate Summary

Company Summary

Products

Pluristem Therapeutics, Inc.

  • Table 11-44: Pluristem Therapeutics Corporate Summary

Company Summary

Products

Sangamo Therapeutics

  • Table 11-45: Sangamo Therapeutics Corporate Summary

Company Summary

Products

Sanofi

  • Table 11-46: Sanofi Corporate Summary

Company Summary

Products

Sotio a.s.

  • Table 11-47: Sotio Corporate Summary

Company Summary

Products

Spark Therapeutics

  • Table 11-48: Spark Therapeutics Corporate Summary

Company Summary

Products

Tessa Therapeutics, Ltd.

  • Table 11-49: Tessa Therapeutics Corporate Summary

Company Summary

Products

uniQure N.V.

  • Table 11-50:  UniQure Corporate Summary

Company Summary

Products

VBL Therapeutics (Vascular Biogenics Ltd.)

  • Table 11-51: VBL Therapeutics Corporate Summary

Company Summary

Products

Vericel Corporation

  • Table 11-52: Vericel Corporate Summary

Company Summary

Products

 

    Cell and Gene Therapy Market Dynamics by Disease Type: Development, Trends, and Forecasts, 4th Edition (2024-2030)
    April 11, 2025
    Cell and Gene Therapy Market Deals: Investment, M&A, and Partnerships, 2021-2025 (3rd Edition)
    February 13, 2025
    Cell and Gene Therapy Deals Analysis, 2021-2024
    June 3, 2024
    Cell Therapy and Gene Therapy Markets (Markets by Disease Type), 2023-2029
    April 30, 2024

Related products

  • Placeholder image

    Worldwide Market for Prescription Dermatological Drugs – 4th Edition, The

    $3,500.00 – $7,000.00
  • Placeholder image

    The Market for Lead Optimization Tools and Services: Applying the New “Omics” to Enhance Drug Discovery

    $1,875.00 – $3,750.00
  • Placeholder image

    World Market for Anti-infectives Volume III: The World Market for Antiviral Medications, The

    $1,875.00 – $3,750.00
  • Placeholder image

    Emerging Cancer Vaccine Market, The

    $3,500.00 – $7,000.00

Contact Us

  • 671 North Glebe Road, Suite 1610 Arlington, VA 22203 United States

  • Email Us

  • 703-778-3080

  • Send us a message!

Pay Invoice

  • Pay an Invoice by Credit Card

Follow Us!

Latest Blogs

  • 4 Fascinating Facts About Cancer Diagnostics March 4, 2025
  • Food Animal Diagnostics Market: Spotlight on Disease Testing Amid Bird Flu Surge February 20, 2025
  • Custom Competitive Intelligence (CI) Research: A New Strategic Imperative For Lab Diagnostics Companies  February 19, 2025
  • The Rise of Pharmacodiagnostics in the $10 Billion Global Cancer Diagnostics Market February 1, 2025
  • IVD Trends to Watch: Personalized Medicine Adds Precision to Diagnostic Testing January 2, 2025

Sitemap

  • Home
  • About
  • Blog
  • Contact
  • Sitemap

Your Data and Privacy

  • View our Privacy Policy
  • GDPR Statement
  • Privacy Settings

About Us

Kalorama Information, part of Science and Medicine Group, has been a leading publisher of market research in medical markets, including the biotechnology, diagnostics, medical device, and pharmaceutical industries for more than 30 years. Our comprehensive, timely, quality research and innovative approach to analysis and presentation of market intelligence have made Kalorama Information a premier source of market information for top industry decision makers.

Visit Science and Medicine Group
Cell and Gene Therapy Deals: Financings, Partnering, M&A, Technology Transfers,...The World Market for Veterinary Diagnostics, 5th Edition
Scroll to top